Exact Mass: 287.1803

Exact Mass Matches: 287.1803

Found 114 metabolites which its exact mass value is equals to given mass value 287.1803, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

   

4-aminoestra-1(10),2,4-triene-3,17-diol

4-Aminoestra-1,3,5(10)-triene-3,17beta-diol

C18H25NO2 (287.1885)


   

2-Aminoestradiol

2-Aminoestra-1,3,5(10)-triene-3,17beta-diol; 2-Aminoestradiol

C18H25NO2 (287.1885)


   

N-[2-(4-Prenyloxyphenyl)ethyl]tiglamide

(2E)-2-Methyl-N-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidate

C18H25NO2 (287.1885)


N-[2-(4-Prenyloxyphenyl)ethyl]tiglamide is a constituent of Boronia megastigma (brown boronia). Constituent of Boronia megastigma (brown boronia)

   

3-Hydroxyhept-4-enoylcarnitine

3-[(3-hydroxyhept-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.1733)


3-hydroxyhept-4-enoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyhept-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxyhept-4-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxyhept-4-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5E)-3-Hydroxyhept-5-enoylcarnitine

3-[(3-hydroxyhept-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.1733)


(5E)-3-hydroxyhept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5E)-3-hydroxyhept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5E)-3-hydroxyhept-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5E)-3-hydroxyhept-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxyhept-5-enoylcarnitine

3-[(2-hydroxyhept-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.1733)


2-hydroxyhept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyhept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-hydroxyhept-5-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-hydroxyhept-5-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Oxoheptanoylcarnitine

3-[(3-oxoheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C14H25NO5 (287.1733)


3-Oxoheptanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxoheptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Oxoheptanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Oxoheptanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-NONYL-4-HYDROXYQUINOLINE N-OXIDE

2-NONYL-4-HYDROXYQUINOLINE N-OXIDE

C18H25NO2 (287.1885)


   

(4-oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl)methyl 2,3-dihydroxy-3-methylpentanoate

(4-oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl)methyl 2,3-dihydroxy-3-methylpentanoate

C14H25NO5 (287.1733)


   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-2-methylpropanamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-N-methyl-2-methylpropanamide

C18H25NO2 (287.1885)


   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-3-methylbutanamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]-3-methylbutanamide

C18H25NO2 (287.1885)


   
   

8-Aza-D-homo-oestradiol

8-Aza-D-homo-oestradiol

C18H25NO2 (287.1885)


   

(2S)-3-(2,3-Dihydroxy-3-methylbutyl)-6-(3-methyl-2-butenyl)indole|3-Methyl-1-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-2,3-butanediol

(2S)-3-(2,3-Dihydroxy-3-methylbutyl)-6-(3-methyl-2-butenyl)indole|3-Methyl-1-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-2,3-butanediol

C18H25NO2 (287.1885)


   

leiocarpadiol

leiocarpadiol

C18H25NO2 (287.1885)


   

(n-Nonanol-9)-2-chinolon-4|2-(9-hydroxy-nonyl)-1H-quinolin-4-one

(n-Nonanol-9)-2-chinolon-4|2-(9-hydroxy-nonyl)-1H-quinolin-4-one

C18H25NO2 (287.1885)


   

1-Methyl-8-methoxy-2-heptylquinolin-4(1H)-one

1-Methyl-8-methoxy-2-heptylquinolin-4(1H)-one

C18H25NO2 (287.1885)


   

(2R)-3-(1,3-Dihydroxy-3-methylbut-2-yl)-6-(3-methyl-2-butenyl)indole|3-Methyl-2-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-1,3-butanediol

(2R)-3-(1,3-Dihydroxy-3-methylbut-2-yl)-6-(3-methyl-2-butenyl)indole|3-Methyl-2-[6-(3-methyl-2-butenyl)-1H-indol-3-yl]-1,3-butanediol

C18H25NO2 (287.1885)


   

1-3-guanidinopropyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline

1-3-guanidinopropyl-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline

C15H21N5O (287.1746)


   

(E,E)-N-(4-Hydroxyphenethyl)-2,4-decadienamide

(E,E)-N-(4-Hydroxyphenethyl)-2,4-decadienamide

C18H25NO2 (287.1885)


   

(E,E)-2,4-decadienoic acid p-hydroxyphenethylamide|Deca-2t,4t-diensaeure-(4-hydroxyphenyl-aethyl)-amid

(E,E)-2,4-decadienoic acid p-hydroxyphenethylamide|Deca-2t,4t-diensaeure-(4-hydroxyphenyl-aethyl)-amid

C18H25NO2 (287.1885)


   
   
   
   
   
   
   
   
   
   

PQS-C9 and NQNO mixture, 2-nonyl-3-hydroxy 4(1H)-quinolone

PQS-C9 and NQNO mixture, 2-nonyl-3-hydroxy 4(1H)-quinolone

C18H25NO2 (287.1885)


   
   
   
   
   
   
   
   

N-[2-(4-Prenyloxyphenyl)ethyl]tiglamide

(2E)-2-methyl-N-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enamide

C18H25NO2 (287.1885)


   

NA 18:6;O

Deca-2E,4E-dienoic acid 4-hydroxy-2-phenylethylamide

C18H25NO2 (287.1885)


   

7-Dibutylamino-4-methyl coumarin

7-Dibutylamino-4-methyl coumarin

C18H25NO2 (287.1885)


   

N-(9-phenyl-1-oxaspiro[5.5]undecan-4-yl)acetamide

N-(9-phenyl-1-oxaspiro[5.5]undecan-4-yl)acetamide

C18H25NO2 (287.1885)


   

tert-Butyl 2,3-dihydrospiro[indene-1,4-piperidine]-1-carboxylate

tert-Butyl 2,3-dihydrospiro[indene-1,4-piperidine]-1-carboxylate

C18H25NO2 (287.1885)


   

tert-Butyl 3-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-1-carboxylate

tert-Butyl 3-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-1-carboxylate

C14H25NO5 (287.1733)


   

4,4-(2-Ethyl-2-nitrotrimethylene)dimorpholine

4,4-(2-ethyl-2-nitropropane-1,3-diyl)bismorpholine

C13H25N3O4 (287.1845)


   

(2R,3R)-BOC-dolaproine

(2R,3R)-BOC-dolaproine

C14H25NO5 (287.1733)


   

(R)-BoroVal-(+)-Pinanediol-HCl

(R)-BoroVal-(+)-Pinanediol-HCl

C14H27BClNO2 (287.1823)


   

Gapromidine

Gapromidine

C14H21N7 (287.1858)


   

2-(DI-TERT-BUTYLPHOSPHINO)-1-PHENYL-1H-PYRROLE

2-(DI-TERT-BUTYLPHOSPHINO)-1-PHENYL-1H-PYRROLE

C18H26NP (287.1803)


   

1-BOC-4-ETHOXYCARBONYLMETHOXYPIPERIDINE

1-BOC-4-ETHOXYCARBONYLMETHOXYPIPERIDINE

C14H25NO5 (287.1733)


   

4-AMINO-CHROMAN-8-CARBONITRILEHYDROCHLORIDE

4-AMINO-CHROMAN-8-CARBONITRILEHYDROCHLORIDE

C14H25NO5 (287.1733)


   

1-Piperidinecarboxylic acid, 4-(aminoiminomethyl)-, 1,1-dimethylethyl ester, acetate (1:1)

1-Piperidinecarboxylic acid, 4-(aminoiminomethyl)-, 1,1-dimethylethyl ester, acetate (1:1)

C13H25N3O4 (287.1845)


   

Moxazocine

Moxazocine

C18H25NO2 (287.1885)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   

Allylprodine

Allylprodine

C18H25NO2 (287.1885)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   
   

tert-butyl 4-(2-ethoxy-2-oxoethyl)-4-hydroxypiperidine-1-carboxylate

tert-butyl 4-(2-ethoxy-2-oxoethyl)-4-hydroxypiperidine-1-carboxylate

C14H25NO5 (287.1733)


   

(R,S)-A-N-BOC-AMINO-B-HYDROXY-CYCLOHEXANEPROPANIC ACID

(R,S)-A-N-BOC-AMINO-B-HYDROXY-CYCLOHEXANEPROPANIC ACID

C14H25NO5 (287.1733)


   

(1S,3R,4R)-3-(Boc-aMino)-4-hydroxy-cyclohexanecarboxylic acid ethyl ester

(1S,3R,4R)-3-(Boc-aMino)-4-hydroxy-cyclohexanecarboxylic acid ethyl ester

C14H25NO5 (287.1733)


   

Tofacitinib Impurity E

Tofacitinib Impurity E

C15H21N5O (287.1746)


   

triplal / ethyl anthranilate schiffs base

triplal / ethyl anthranilate schiffs base

C18H25NO2 (287.1885)


   

citronellal / methyl anthranilate schiffs base

citronellal / methyl anthranilate schiffs base

C18H25NO2 (287.1885)


   

2-Aminoestra-1,3,5(10)-triene-3,17beta-diol

2-Aminoestra-1,3,5(10)-triene-3,17beta-diol

C18H25NO2 (287.1885)


   

4-Aminoestra-1,3,5(10)-triene-3,17beta-diol

4-Aminoestra-1,3,5(10)-triene-3,17beta-diol

C18H25NO2 (287.1885)


   

N4-(4-methoxyphenyl)-1,3,5-triazaspiro[5.5]undeca-1,4-diene-2,4-diamine

N4-(4-methoxyphenyl)-1,3,5-triazaspiro[5.5]undeca-1,4-diene-2,4-diamine

C15H21N5O (287.1746)


   
   

L-Valyl-L-leucylglycine

L-Valyl-L-leucylglycine

C13H25N3O4 (287.1845)


   

Glycyl-L-isoleucyl-L-valine

Glycyl-L-isoleucyl-L-valine

C13H25N3O4 (287.1845)


   

3-Oxoheptanoylcarnitine

3-Oxoheptanoylcarnitine

C14H25NO5 (287.1733)


   

3-Hydroxyhept-4-enoylcarnitine

3-Hydroxyhept-4-enoylcarnitine

C14H25NO5 (287.1733)


   

2-Hydroxyhept-5-enoylcarnitine

2-Hydroxyhept-5-enoylcarnitine

C14H25NO5 (287.1733)


   

(5E)-3-Hydroxyhept-5-enoylcarnitine

(5E)-3-Hydroxyhept-5-enoylcarnitine

C14H25NO5 (287.1733)


   

3,4-Quinolinediol, 2-nonyl-

3,4-Quinolinediol, 2-nonyl-

C18H25NO2 (287.1885)


   

Leu-Val-Gly

Leu-Val-Gly

C13H25N3O4 (287.1845)


A tripeptide composed of L-leucine, L-valine and glycine joined in sequence by peptide linkages.

   

Glycyl-valyl-isoleucine

Glycyl-valyl-isoleucine

C13H25N3O4 (287.1845)


   
   

Glycyl-valyl-leucine

Glycyl-valyl-leucine

C13H25N3O4 (287.1845)


   
   
   
   
   
   
   
   
   

4-[3-(4-Acetamidobutylamino)propylamino]-4-oxobutanoic acid

4-[3-(4-Acetamidobutylamino)propylamino]-4-oxobutanoic acid

C13H25N3O4 (287.1845)


   

4-[4-(3-Acetamidopropylamino)butylamino]-4-oxobutanoic acid

4-[4-(3-Acetamidopropylamino)butylamino]-4-oxobutanoic acid

C13H25N3O4 (287.1845)


   
   
   
   
   
   
   
   
   
   

3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

C18H25NO2 (287.1885)


   

n-{3-[(1r)-6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl]propyl}guanidine

n-{3-[(1r)-6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl]propyl}guanidine

C15H21N5O (287.1746)


   

2-[(2r,6s)-6-[(2s)-2-hydroxybutyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

2-[(2r,6s)-6-[(2s)-2-hydroxybutyl]-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

C18H25NO2 (287.1885)


   

n-(3-{6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl}propyl)guanidine

n-(3-{6-hydroxy-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-yl}propyl)guanidine

C15H21N5O (287.1746)


   

2-[6-(2-hydroxybutyl)-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

2-[6-(2-hydroxybutyl)-1-methyl-3,6-dihydro-2h-pyridin-2-yl]-1-phenylethanone

C18H25NO2 (287.1885)


   

(2r)-3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

(2r)-3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

C18H25NO2 (287.1885)


   

1-hydroxy-2-nonylquinolin-4-one

1-hydroxy-2-nonylquinolin-4-one

C18H25NO2 (287.1885)


   

2-(9-hydroxynonyl)-1h-quinolin-4-one

2-(9-hydroxynonyl)-1h-quinolin-4-one

C18H25NO2 (287.1885)


   

2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

C18H25NO2 (287.1885)


   

(2e)-2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

(2e)-2-methyl-n-(2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)but-2-enimidic acid

C18H25NO2 (287.1885)


   

(2s)-3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

(2s)-3-methyl-1-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-2,3-diol

C18H25NO2 (287.1885)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,2-dimethylpropanamide

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,2-dimethylpropanamide

C18H25NO2 (287.1885)


   

n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

C18H25NO2 (287.1885)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-3-methylbutanimidic acid

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-3-methylbutanimidic acid

C18H25NO2 (287.1885)


   

3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

3-methyl-2-[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]butane-1,3-diol

C18H25NO2 (287.1885)


   

3-methyl-1-[3-(2-methylbut-3-en-2-yl)-1h-indol-7-yl]butane-2,3-diol

3-methyl-1-[3-(2-methylbut-3-en-2-yl)-1h-indol-7-yl]butane-2,3-diol

C18H25NO2 (287.1885)


   

2-heptyl-8-methoxy-1-methylquinolin-4-one

2-heptyl-8-methoxy-1-methylquinolin-4-one

C18H25NO2 (287.1885)


   

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

(2e,4e)-n-[2-(4-hydroxyphenyl)ethyl]deca-2,4-dienimidic acid

C18H25NO2 (287.1885)